New Respiratory Infection Tests Pose Challenges To FDA, Industry
This article was originally published in The Gray Sheet
Diagnostics that quickly identify respiratory viral infections could help curb antibiotic abuse, but getting new tests to market will require a closer meeting of the minds between FDA and industry
You may also be interested in...
Luminex launched its xTAG Respiratory Viral Panel Jan. 3, with plans for a quick ramp-up to capture market in the current flu season
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.